GSK’s Anoro Ellipta Needs CV Postmarket Study, FDA Panel Says In Endorsement
This article was originally published in The Pink Sheet Daily
Executive Summary
Pulmonary-Allergy Drugs Advisory Committee votes in favor of what could become the first-approved LAMA/LABA combo for COPD but wants postmarket safety study in patients with more severe cardiovascular disease.
You may also be interested in...
Signs Of R&D Progress For GSK, Though China Overhang Remains
With four new drug approvals notched under its belt in four months, GlaxoSmithKline had several potential growth drivers to highlight during its third quarter earnings call, helping to deflect attention away from the bribery scandal in China.
Advair Bioequivalence Guidance Falls Short of GSK’s Requests
FDA’s draft guidance requires clinical study but sets a lower bar to generics of GSK’s blockbuster asthma and COPD treatment than company proposed; standards appear poised for warm reception from generic challengers.
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.